Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to evaluate factors related to outcomes of fecal microbiota transplantation (FMT) in patients with Clostridioides difficile infection (CDI) and viability of frozen stock for FMT. Methods: Clinical data of patients who had received FMT for CDI were prospectively collected. Next-generation 16S rRNA gene sequencing of bacteria was performed from donors’ and recipients’ stool. Colony-forming units (CFUs) of cultures from frozen stock solutions for FMT were measured at 0, 4, 8, 12, 24, 48 weeks after preparation of the solutions. Results: In total, 25 FMT procedures were performed in 20 cases (14 fresh and 11 frozen FMT). Forty-five percent of cases involved fulminant CDI. The overall success rate was 55% after the 1st FMT and 75% after the 2nd FMT. The success rate was significantly higher in partially treated CDI than in refractory CDI (100% vs 71.4%; p=0.001). In successful cases only, the decrease in alpha-diversity in the recipient stool microbiomes was recovered after FMT to a level similar to that in donor stools. There was a significant difference in the microbiome composition in pre-FMT recipients’ stool between successful and failed cases (p=0.001). The CFUs of frozen solution for FMT did not decrease for 48 weeks in both aerobic and anaerobic cultures. Conclusions: FMT is highly effective in partially treated CDI but not in refractory CDI. The microbiome differs between failed and successful cases. Frozen stock for FMT is viable up to 48 weeks.
Abstract
Background/Aims: The aim of this study was to evaluate factors related to outcomes of fecal microbiota transplantation (FMT) in patients with Clostridioides difficile infection (CDI) and viability of frozen stock for FMT. Methods: Clinical data of patients who had received FMT for CDI were prospectively collected. Next-generation 16S rRNA gene sequencing of bacteria was performed from donors’ and recipients’ stool. Colony-forming units (CFUs) of cultures from frozen stock solutions for FMT were measured at 0, 4, 8, 12, 24, 48 weeks after preparation of the solutions. Results: In total, 25 FMT procedures were performed in 20 cases (14 fresh and 11 frozen FMT). Forty-five percent of cases involved fulminant CDI. The overall success rate was 55% after the 1st FMT and 75% after the 2nd FMT. The success rate was significantly higher in partially treated CDI than in refractory CDI (100% vs 71.4%; p=0.001). In successful cases only, the decrease in alpha-diversity in the recipient stool microbiomes was recovered after FMT to a level similar to that in donor stools. There was a significant difference in the microbiome composition in pre-FMT recipients’ stool between successful and failed cases (p=0.001). The CFUs of frozen solution for FMT did not decrease for 48 weeks in both aerobic and anaerobic cultures. Conclusions: FMT is highly effective in partially treated CDI but not in refractory CDI. The microbiome differs between failed and successful cases. Frozen stock for FMT is viable up to 48 weeks.
참고문헌 (29)
- McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin Infect Dis, 66, pp.987~994 (2018)
- Jung Hoon Song, "Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention", Gut and Liver, 13(1), pp.16~24 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Quraishi MN, "Systematic review with meta-analysis : the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection", Aliment Pharmacol Ther, 46, pp.479~493 (2017)
- Mullish BH, "The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications : joint British Society of Gastroenterology(BSG)and Healthcare Infection Society(HIS)guidelines", Gut, 67, pp.1920~1941 (2018)
- Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
- Kelly CR, "Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients", Am J Gastroenterol, 109, pp.1065~1071 (2014)
- Zainah H, "Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection", Dig Dis Sci, 60, pp.181~185 (2015)
- Kristin E. Burke, "Clostridium difficile Infection: A Worldwide Disease", Gut and Liver, 8(1), pp.1~6 (2014), 거트앤리버 소화기연관학회협의회
- Cammarota G, "European consensus conference on faecal microbiota transplantation in clinical practice", Gut, 66, pp.569~580 (2017)
- Gweon TG, "Fecal microbiota transplantation using upper gastrointestinal tract for the treatment of refractory or severe complicated Clostridium difficile infection in elderly patients in poor medical condition : the first study in an Asian country", Gastroenterol Res Pract, 2016, pp.2687605~ (2016)
- Cohen NA, "A retrospective comparison of fecal microbial transplantation methods for recurrent Clostridium difficile infection", Isr Med Assoc J, 18, pp.594~599 (2016)
- Chun J, "The analysis of oral microbial communities of wild-type and toll-like receptor 2-deficient mice using a 454 GS FLX Titanium pyrosequencer", BMC Microbiol, 10, pp.101~ (2010)
- Hur M, "Effect of genetically modified poplars on soil microbial communities during the phytoremediation of waste mine tailings", Appl Environ Microbiol, 77, pp.7611~7619 (2011)
- Kim BS, "Impact of enrofloxacin on the human intestinal microbiota revealed by comparative molecular analysis", Anaerobe, 18, pp.310~320 (2012)
- Yoon SH, "Introducing EzBioCloud : a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies", Int J Syst Evol Microbiol, 67, pp.1613~1617 (2017)
- Kelly CR, "Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection : a randomized trial", Ann Intern Med, 165, pp.609~616 (2016)
- Kao D, "Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection : a randomized clinical trial", JAMA, 318, pp.1985~1993 (2017)
- van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
- Cammarota G, "Randomised clinical trial : faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection", Aliment Pharmacol Ther, 41, pp.835~843 (2015)
- Hota SS, "Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection : an open-label, randomized controlled trial", Clin Infect Dis, 64, pp.265~271 (2017)
- Feuerstadt P, "The evolution of urban C. difficile infection(CDI) : CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008", Am J Gastroenterol, 109, pp.1265~1276 (2014)
- Aroniadis OC, "Long-term follow-up study of fecal microbiota transplantation for severe and", or complicated Clostridium difficile infection : a multicenter experience, 2016, pp.50, 398~402
- Agrawal M, "The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals", J Clin Gastroenterol, 50, pp.403~407 (2016)
- Ooijevaar RE, "Update of treatment algorithms for Clostridium difficile infection", Clin Microbiol Infect, 24, pp.452~462 (2018)
- Li X, "Clinical efficacy and microbiome changes following fecal microbiota transplantation in children with recurrent Clostridium difficile infection", Front Microbiol, 9, pp.2622~ (2018)
- Seekatz AM, "Recovery of the gut microbiome following fecal microbiota transplantation", mBio, 5, pp.e00893~14 (2014)
- Costello SP, "Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective : clinical efficacy and bacterial viability data", Aliment Pharmacol Ther, 42, pp.1011~1018 (2015)
- Terveer EM, "How to: establish and run a stool bank", Clin Microbiol Infect, 23, pp.924~930 (2017)
- Mullish BH, "Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection", Gut, 68, pp.1791~1800 (2019)